These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25294903)

  • 1. DNA methylation status of key cell-cycle regulators such as CDKNA2/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors.
    Klajic J; Busato F; Edvardsen H; Touleimat N; Fleischer T; Bukholm I; Børresen-Dale AL; Lønning PE; Tost J; Kristensen VN
    Clin Cancer Res; 2014 Dec; 20(24):6357-66. PubMed ID: 25294903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and epigenetic changes in p21 and p21B do not correlate with resistance to doxorubicin or mitomycin and 5-fluorouracil in locally advanced breast cancer.
    Staalesen V; Leirvaag B; Lillehaug JR; Lønning PE
    Clin Cancer Res; 2004 May; 10(10):3438-43. PubMed ID: 15161699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
    Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
    Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
    Geisler S; Børresen-Dale AL; Johnsen H; Aas T; Geisler J; Akslen LA; Anker G; Lønning PE
    Clin Cancer Res; 2003 Nov; 9(15):5582-8. PubMed ID: 14654539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival.
    Nordgard SH; Alnaes GI; Hihn B; Lingjaerde OC; Liestøl K; Tsalenko A; Sørlie T; Lønning PE; Børresen-Dale AL; Kristensen VN
    Int J Cancer; 2008 Aug; 123(3):577-85. PubMed ID: 18498133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
    Nakamura Y; Oshima K; Naoi Y; Nakayama T; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Jul; 134(1):229-36. PubMed ID: 22315133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.
    Dejeux E; Rønneberg JA; Solvang H; Bukholm I; Geisler S; Aas T; Gut IG; Børresen-Dale AL; Lønning PE; Kristensen VN; Tost J
    Mol Cancer; 2010 Mar; 9():68. PubMed ID: 20338046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
    Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
    Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
    Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
    PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter methylation of cyclin A1 is associated with human papillomavirus 16 induced head and neck squamous cell carcinoma independently of p53 mutation.
    Weiss D; Basel T; Sachse F; Braeuninger A; Rudack C
    Mol Carcinog; 2011 Sep; 50(9):680-8. PubMed ID: 21563216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Abnormal methylation of several tumor suppressor genes in sporadic breast cancer].
    Zemliakova VV; Zhevlova AI; Strel'nikov VV; Liubchenko LN; Vishnevskaia IaV; Tret'iakova VA; Zaletaev DV; Nemtsova MV
    Mol Biol (Mosk); 2003; 37(4):696-703. PubMed ID: 12942643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
    Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
    Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation of BRCA1 and APC aberrant methylation with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer].
    Yuan P; Xu Y; Ouyang T; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT; Li JF
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):282-6. PubMed ID: 19615284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
    Hess KR; Anderson K; Symmans WF; Valero V; Ibrahim N; Mejia JA; Booser D; Theriault RL; Buzdar AU; Dempsey PJ; Rouzier R; Sneige N; Ross JS; Vidaurre T; Gómez HL; Hortobagyi GN; Pusztai L
    J Clin Oncol; 2006 Sep; 24(26):4236-44. PubMed ID: 16896004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
    Kandioler-Eckersberger D; Ludwig C; Rudas M; Kappel S; Janschek E; Wenzel C; Schlagbauer-Wadl H; Mittlböck M; Gnant M; Steger G; Jakesz R
    Clin Cancer Res; 2000 Jan; 6(1):50-6. PubMed ID: 10656431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of DNA methylation and gene expression in radiation-resistant head and neck tumors.
    Chen X; Liu L; Mims J; Punska EC; Williams KE; Zhao W; Arcaro KF; Tsang AW; Zhou X; Furdui CM
    Epigenetics; 2015; 10(6):545-61. PubMed ID: 25961636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
    Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.
    Kawamoto K; Enokida H; Gotanda T; Kubo H; Nishiyama K; Kawahara M; Nakagawa M
    Biochem Biophys Res Commun; 2006 Jan; 339(3):790-6. PubMed ID: 16316628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
    Foedermayr M; Sebesta M; Rudas M; Berghoff AS; Promberger R; Preusser M; Dubsky P; Fitzal F; Gnant M; Steger GG; Weltermann A; Zielinski CC; Zach O; Bartsch R
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):771-8. PubMed ID: 24526178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.